Arrowhead Research Corp. (ARWR) Given a $10.00 Price Target at Chardan Capital
A number of other equities research analysts also recently issued reports on ARWR. Piper Jaffray Cos. decreased their price objective on Arrowhead Research Corp. from $13.00 to $8.00 and set an overweight rating on the stock in a research report on Wednesday, August 10th. Cantor Fitzgerald reaffirmed a buy rating on shares of Arrowhead Research Corp. in a research note on Thursday. Finally, William Blair started coverage on Arrowhead Research Corp. in a research note on Friday, August 19th. They set an outperform rating on the stock. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of Buy and an average price target of $10.11.
Arrowhead Research Corp. (NASDAQ:ARWR) traded up 1.438% during trading on Thursday, reaching $7.405. The company had a trading volume of 603,591 shares. Arrowhead Research Corp. has a one year low of $3.07 and a one year high of $8.22. The company’s market capitalization is $449.85 million. The firm’s 50 day moving average is $7.03 and its 200 day moving average is $5.94.
Arrowhead Research Corp. (NASDAQ:ARWR) last issued its quarterly earnings data on Tuesday, August 9th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.05. Arrowhead Research Corp. had a negative return on equity of 100.50% and a negative net margin of 48,980.81%. The business had revenue of $39.58 million for the quarter, compared to the consensus estimate of $0.05 million. During the same period in the prior year, the business posted ($0.27) earnings per share. The company’s quarterly revenue was down 68.0% compared to the same quarter last year. On average, equities research analysts predict that Arrowhead Research Corp. will post ($1.31) earnings per share for the current year.
In other Arrowhead Research Corp. news, CFO Kenneth Allen Myszkowski sold 6,900 shares of the company’s stock in a transaction on Tuesday, August 23rd. The stock was sold at an average price of $8.00, for a total transaction of $55,200.00. Following the completion of the sale, the chief financial officer now owns 128,789 shares in the company, valued at $1,030,312. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 3.90% of the company’s stock.
Hedge funds have recently modified their holdings of the stock. California Public Employees Retirement System acquired a new stake in shares of Arrowhead Research Corp. during the second quarter valued at approximately $1,462,000. Point72 Asset Management L.P. acquired a new stake in shares of Arrowhead Research Corp. during the second quarter valued at approximately $1,362,000. KCG Holdings Inc. acquired a new stake in shares of Arrowhead Research Corp. during the second quarter valued at approximately $439,000. Emerald Acquisition Ltd. acquired a new stake in shares of Arrowhead Research Corp. during the second quarter valued at approximately $390,000. Finally, Vanguard Group Inc. raised its stake in shares of Arrowhead Research Corp. by 2.6% in the second quarter. Vanguard Group Inc. now owns 2,446,346 shares of the company’s stock valued at $13,015,000 after buying an additional 62,229 shares in the last quarter. Hedge funds and other institutional investors own 33.92% of the company’s stock.
About Arrowhead Research Corp.
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. ARC-520 is designed to treat chronic hepatitis B virus (HBV) infection.
Receive News & Stock Ratings for Arrowhead Research Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Research Corp. and related stocks with our FREE daily email newsletter.